X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Annamycin is a "next generation" anthracycline, that has been shown to be less cardiotoxic compared to other anthracycline, such as doxorubicin, and to avoid multidrug resistance, so the use of Annamycin may not face the same dose limitations imposed on doxorubicin.
Lead Product(s): Annamycin,Cytarabine
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Polish National Center for Research and Development
Deal Size: $6.7 million Upfront Cash: Undisclosed
Deal Type: Funding May 11, 2021
Details:
Berubicin is a second-generation anthracycline candidate for the treatment of a number of Central Nervous System Cancers, including Glioblastoma Multiforme (GBM) and Malignant Gliomas.
Lead Product(s): Berubicin Hydrochloride
Therapeutic Area: Oncology Product Name: RTA 744
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 27, 2021
Details:
WPD entered into the amendment of its February 2019 sublicense from Moleculin of certain IP rights, including the rights to Annamycin, WP1066 and WP1122 portfolios to research, develop, manufacture, use, import, offer and sell products derived from these portfolios.
Lead Product(s): Annamycin
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Recipient: Moleculin Biotech
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Funding March 30, 2021
Details:
Annamycin is a "next generation" anthracycline that has recently been shown in animal models to accumulate in the lungs at up to 30-fold the level of doxorubicin. Annamycin has also demonstrated a lack of cardiotoxicity in recently conducted human clinical trials for AML.
Lead Product(s): Annamycin
Therapeutic Area: Oncology Product Name: L-ANN
Highest Development Status: Phase IProduct Type: Small molecule
Recipient: Moleculin Biotech
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 30, 2021
Details:
Under the collaborative agreement, WPD is not required to pay Dermin or grant a royalty for the rights transferred, but is required to provide Dermin with all its research data, if any, which Dermin may use for the further development of WP1122 as an anti-glioma drug.
Lead Product(s): WP1122
Therapeutic Area: Infections and Infectious Diseases Product Name: WP1122
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Dermin
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration August 17, 2020
Details:
Under the terms of the development agreement with WPD Pharmaceuticals, CNS agreed to fund a portion of the development costs of WP1122 and other drug candidates for antiviral indications in exchange for certain economic rights.
Lead Product(s): WP1122
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: CNS Pharmaceuticals
Deal Size: $1.0 million Upfront Cash: $0.2 million
Deal Type: Agreement May 27, 2020
Details:
The US Phase 1 trial shows the safety of Annamycin in a phase I trial setting when delivered to patients at or below the lifetime maximum anthracycline dose established by the FDA.
Lead Product(s): Annamycin
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 23, 2020
Details:
Independent research on in WPD Pharmaceutical's WP1122 drug compound found 2-deoxy-D-glucose (“2-DG”) to reduce replication of SARS-CoV-2.
Lead Product(s): WP1122
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 09, 2020
Details:
CNS Pharmaceuticals has entered into an agreement with WPD Pharmaceuticals Inc for the development of several preclinical drug candidates including WP1122.
Lead Product(s): WP1122
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Small molecule
Partner/Sponsor/Collaborator: CNS Pharmaceuticals
Deal Size: $1.0 million Upfront Cash: $0.2 million
Deal Type: Agreement March 23, 2020
Details:
WP1066 drug candidate received FDA approval for Investigational New Drug status to be used in a Phase 1 clinical trial for recurrent or refractory malignant brain tumors in children.
Lead Product(s): WP1066
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 20, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
